Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in
clinical stage IA using the monoclonal anti-CD20 antibody rituximab